

# Sandra J Gendler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7355780/publications.pdf>

Version: 2024-02-01

12  
papers

553  
citations

1040056

9  
h-index

1281871

11  
g-index

12  
all docs

12  
docs citations

12  
times ranked

954  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Flow Cytometry-Based Assay for Procoagulant Platelet Polyphosphate. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 369-373.	1.5	14
2	Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. <i>ChemBioChem</i> , 2018, 19, 121-125.	2.6	14
3	Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. <i>Oncotarget</i> , 2017, 8, 10785-10808.	1.8	14
4	Chemotherapy can induce weight normalization of morbidly obese mice despite undiminished ingestion of high fat diet. <i>Oncotarget</i> , 2017, 8, 5426-5438.	1.8	9
5	Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes. <i>Biomolecules</i> , 2016, 6, 31.	4.0	9
6	Muc1 enhances the $\beta$ -catenin protective pathway during ischemia-reperfusion injury. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, F569-F579.	2.7	26
7	Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide. <i>Chemical Communications</i> , 2015, 51, 10214-10217.	4.1	51
8	Muc1 is protective during kidney ischemia-reperfusion injury. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, F1452-F1462.	2.7	35
9	Inhibition of Adaptive Immunity by IL9 Can Be Disrupted to Achieve Rapid T-cell Sensitization and Rejection of Progressive Tumor Challenges. <i>Cancer Research</i> , 2014, 74, 6845-6855.	0.9	43
10	Immune and Anticancer Responses Elicited by Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccines Modified by a TLR2 or TLR9 Agonist. <i>ChemBioChem</i> , 2014, 15, 1508-1513.	2.6	60
11	Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 261-266.	7.1	278
12	Letter for Joyce. <i>Glycoconjugate Journal</i> , 2001, 18, 839-840.	2.7	0